金融界1月9日消息,据CDE官网沟通交流公示,于1月9日收到浙江昌海制药有限公司申请的“III类会议”,当前状态“处理中”。
根据《药物研发与技术审评沟通交流管理办法》(2020年第48号通告),沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议,就关键阶段重大问题进行沟通交流,Ⅲ类会议一般安排在申请后75日内召开。
浙江昌海制药有限公司,成立于2016年,位于绍兴市,是一家以从事医药制造业为主的企业。企业注册资本63330万人民币。
通过天眼查大数据分析,浙江昌海制药有限公司参与招投标项目45次,专利信息38条,此外企业还拥有行政许可38个。
主要股东信息显示,浙江昌海制药有限公司由浙江医药股份有限公司持股80.9253%、绍兴益元生物医药合伙企业(有限合伙)持股6.474%、绍兴立德生物医药科技合伙企业(有限合伙)持股4.8397%、绍兴立功生物医药合伙企业(有限合伙)持股4.7687%、绍兴立言生物医药科技合伙企业(有限合伙)持股2.9923%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.